Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Afr Health Sci ; 23(4): 266-274, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-38974258

RESUMO

Background: Breast phyllodes tumors (BPT) have variable malignant potential, their histological classification remains insufficient for an accurate diagnosis. Objectives: We attempted to investigate CD10 (Cluster of differentiation 10) and EGFR (Epidermal growth factor receptor) expression in BPT in order to highlight their diagnostic and prognostic values. Methods: Eight patients with BPT are recruited from January 2014 to December 2020 and immunohistochemical assessment of CD10 and EGFR is realized. Results: Median age was 27±15.2, the mean tumor size was 9.63±10.21. Only malignant tumours showed expression for EGFR. Borderline and malignant tumors were CD10 positive. Patients overexpressing CD10 were postmenopausal with great tumor size, 25% of these were sarcomatous. Coexistence of CD10 and EGFR overexpression was found in 25% of cases and was associated with age (P=0.008), tumor size (P=0.030) and hitologic types (P=0.014). PC1 and PC2, were extracted, they accounted cumulatively for 94.7% of the variance of the data analysed, it suggests that patient's age and histological type of tumor have significant association with CD10 and EGFR expression in BPT. Conclusions: EGFR and CD10 overexpressed combined proteins in phyllode tumors constitute, with histopathological parameters, an important prognostic factor as well as a promising potential targets.


Assuntos
Biomarcadores Tumorais , Neoplasias da Mama , Receptores ErbB , Neprilisina , Tumor Filoide , Adolescente , Adulto , Feminino , Humanos , Pessoa de Meia-Idade , Adulto Jovem , Argélia/epidemiologia , Biomarcadores Tumorais/metabolismo , Neoplasias da Mama/patologia , Neoplasias da Mama/metabolismo , Receptores ErbB/metabolismo , Imuno-Histoquímica , Neprilisina/metabolismo , Tumor Filoide/patologia , Tumor Filoide/metabolismo , Prognóstico
2.
Pan Afr Med J ; 38: 88, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33889254

RESUMO

INTRODUCTION: breast cancer is related to age. The young age remains a controversial issue as a prognostic factor and have more aggressive clinical behavior with poor outcome. We aimed for the first time in Algeria to explore on a large cohort of patients the prevalence of the molecular phenotypes and to describe their clinical characteristics and survival. METHODS: medical record of 1140 Algerian patients were analysed and categorized into three age groups: "young" when women were aged below 40 years; "middle-age" when women were aged from 41 to 54 years old and "elder" when women were over 54 years. Baseline categorical variables were analysed using the Chi-square test and survival curves were constructed using Kaplan Meir method. RESULTS: the distribution of the various prognostic factors did not differ significativelly by age groups except for histological types, hormone receptors status and molecular phenotypes. Most patients were luminal A, indeed, young and intermediate age patients were most likely to be luminal A whereas the aged patients were triple negative with the highest mean DFS. Elsewhere young women are considered as human epidermal growth factor receptor 2 (HER2+) or triple negative molecular subtypes involving more rigorous therapeutic monitoring. The high rate of triple negative breast cancer in aged patients may due to genetic predispositions. CONCLUSION: this study sheds light on the histoclinical and molecular characteristics of breast cancer in young patients, which has a good prognosis than their older counterparts. Our results are therefore surprisingly different from what the literature suggests. A further study should understand this uncommon finding.


Assuntos
Neoplasias da Mama/patologia , Neoplasias de Mama Triplo Negativas/patologia , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Argélia , Estudos de Coortes , Feminino , Humanos , Pessoa de Meia-Idade , Fenótipo , Prevalência , Prognóstico , Receptor ErbB-2/metabolismo , Estudos Retrospectivos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA